This is what gets me. They do have drugs on the market throughout the world that they originated, but then sold to fund other studies.
In the scenario where 150 were in investigators choice and 40 were in Aldox (or something similar), I could see how they could arrive at these results when the patients that DID progress, were similar lengths in nature. This would still be a good thing because it would give merit to the extended dosing SPA and support their claims of double ORR and disease control rate.
I wonder why the company doesn't give out actual data figures like they did with the 2b trial. It's almost as if they wanted the price to drop to get shorts to cover.
Nothing in the CYTR articles was false, except the author's name. All the articles did was re-hash the phase 2b data, which in itself was pretty awesome.
Not really. Jefferies holds the vast majority of the short positions. The also have close to 7M shares in warrants from the Jan 2014 offering. They will effectively hold these short positions until results. If results re bad, they make bank. If results are good, the immediately cover and will exercise the warrants.
One thing is certain, 2 months from now, the PPS will not be at this level.
No. They announced it the day after they received it from the FDA. The hold was imposed 22 days after the patient on the compassionate use program died.